A CLINICAL RESEARCH CAREER WORKING SPONSOR-SIDE, CRO-SIDE TO SITE-SIDE AT PARATUS CLINICAL
With
Megan Morrison,
Chief Executive Officer
Paratus Clinical
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Melbourne | December 2025
In July 2025, Paratus Clinical, a Australian provider of dedicated clinical trial services, announced the appointment of Megan Morrison as its new Chief Executive Officer, at the same time as a significant milestone as the company celebrating over a decade of impact in the clinical research space. Paratus now operates a network of five purpose-built, research-only clinics along Australia’s eastern seaboard.
Megan Morrison as the Chief Executive Officer of Paratus Clinical, brings more than 24 years of experience in the clinical research industry. She has held senior leadership roles across sponsor organisations, CROs and clinical sites, giving her a uniquely comprehensive perspective on the challenges and opportunities across the drug development ecosystem.
With a background in pharmacology and a Master of Business Administration, Megan combines scientific expertise with commercial and operational acumen. She is committed to advancing Australia’s role in global clinical research by expanding access to innovative studies, strengthening partnerships with sponsors, and ensuring that high-quality outcomes are delivered for both patients and partners.
In this interview with Australian Health Journal she talks about her career journey, current trends in the industry as well as recent projects. Megan also shares her career advice on being curious, in a frequently changing environment such as clinical research, for the benefit of sponsors getting new therapies to market.
Source: Adapted from Paratus Clinical media releases and website
-
Awareness, diagnosis and treatment of Congenital Hypothyroidism
Australian Health Journal spoke to Associate Professor MIchelle Jack about congenital hypothyroidism and newborn screening and her concerns in the varying thresholds for across different states in Australia. Despite the existence of newborn screening programs since the 1970s, there is still controversy surrounding the appropriate screening levels. Congenital hypothyroidism, affecting about one in 3500 infants, can lead to severe intellectual and physical impairment if not diagnosed early. The condition is mainly caused by the thyroid gland’s failure to develop properly, resulting in insufficient thyroid hormone production.
-
Entering The New Health Frontier
A new parliamentary report ‘The New Frontier: Delivering better health for all Australians’ is recommending significant reforms to the health care system to ensure Australians have better and faster access to the wave of new medicines and technologies.
The bipartisan report makes 31 recommendations to reform Australia’s system for the regulation and reimbursement with the hope that patients will receive faster access to the latest medicines and technologies.
-
Australian Teletrial Program reaches significant milestones in trials and participants
Launched in 2022, the Australian Teletrial Program is an initiative designed to improve access to clinical trials for people living in regional and remote areas of Australia. It uses telemedicine and digital technologies to enable patients to participate in clinical trials without needing to travel long distances to major metropolitan centres, which can often be a barrier to participation for those in rural and isolated locations.
Recently Australian Health Journal met with Kaye Hewson, Director, Australian Teletrials Program, who spoke about the program’s recent achievements.
